Adherence to recommendations for ART and targeted PrEP use among HIV serodiscordant couples in East Africa: the "PrEP as a bridge to ART" strategy.
ART
Adherence
Demonstration project
Kenya
PrEP
Uganda
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
28 Oct 2020
28 Oct 2020
Historique:
received:
25
05
2020
accepted:
15
10
2020
entrez:
29
10
2020
pubmed:
30
10
2020
medline:
15
5
2021
Statut:
epublish
Résumé
PrEP use should be aligned with periods of risk for HIV acquisition. For HIV serodiscordant couples, PrEP can be used as a bridge until the partner living with HIV takes antiretroviral therapy (ART) long enough to achieve viral suppression (the "PrEP as a Bridge to ART" strategy). However, adherence to this strategy is unknown. In a demonstration project in Kenya and Uganda, HIV-uninfected partners of serodiscordant couples were advised to take PrEP until the partner living with HIV took ART for ≥ 6 months. PrEP discontinuation was then recommended unless there were concerns about ART adherence, immediate fertility intentions, or outside partners with unknown HIV/ART status. Electronic adherence monitoring and socio-behavioral questionnaire data were used in logistic regression models to explore completion of this strategy and continuation of PrEP beyond recommendations to stop its use. Among 833 serodiscordant couples, 436 (52%) HIV-uninfected partners completed ≥ 6 months of PrEP as a bridge to ART. Strategy completion was associated with older age (aOR per 5 years = 1.1; p = 0.008) and having fewer children (aOR = 0.9; p = 0.019). Of the 230 participants encouraged to stop PrEP according to strategy recommendations, 170 (74%) did so. PrEP continuation among the remaining 60 participants was associated with more education (aOR = 1.1; p = 0.029), a preference for PrEP over ART (aOR = 3.6; p = 0.026), comfort with managing their serodiscordant relationship (aOR = 0.6; p = 0.046), and believing PrEP makes sex safe (aOR = 0.5; p = 0.026). Half of participants completed the PrEP as a bridge to ART strategy and the majority stopped PrEP as recommended. These findings suggest that targeting PrEP to periods of risk is a promising approach; however, tailoring counseling around aligning PrEP use and HIV risk will be important for optimal strategy implementation.
Sections du résumé
BACKGROUND
BACKGROUND
PrEP use should be aligned with periods of risk for HIV acquisition. For HIV serodiscordant couples, PrEP can be used as a bridge until the partner living with HIV takes antiretroviral therapy (ART) long enough to achieve viral suppression (the "PrEP as a Bridge to ART" strategy). However, adherence to this strategy is unknown.
METHODS
METHODS
In a demonstration project in Kenya and Uganda, HIV-uninfected partners of serodiscordant couples were advised to take PrEP until the partner living with HIV took ART for ≥ 6 months. PrEP discontinuation was then recommended unless there were concerns about ART adherence, immediate fertility intentions, or outside partners with unknown HIV/ART status. Electronic adherence monitoring and socio-behavioral questionnaire data were used in logistic regression models to explore completion of this strategy and continuation of PrEP beyond recommendations to stop its use.
RESULTS
RESULTS
Among 833 serodiscordant couples, 436 (52%) HIV-uninfected partners completed ≥ 6 months of PrEP as a bridge to ART. Strategy completion was associated with older age (aOR per 5 years = 1.1; p = 0.008) and having fewer children (aOR = 0.9; p = 0.019). Of the 230 participants encouraged to stop PrEP according to strategy recommendations, 170 (74%) did so. PrEP continuation among the remaining 60 participants was associated with more education (aOR = 1.1; p = 0.029), a preference for PrEP over ART (aOR = 3.6; p = 0.026), comfort with managing their serodiscordant relationship (aOR = 0.6; p = 0.046), and believing PrEP makes sex safe (aOR = 0.5; p = 0.026).
CONCLUSION
CONCLUSIONS
Half of participants completed the PrEP as a bridge to ART strategy and the majority stopped PrEP as recommended. These findings suggest that targeting PrEP to periods of risk is a promising approach; however, tailoring counseling around aligning PrEP use and HIV risk will be important for optimal strategy implementation.
Identifiants
pubmed: 33115478
doi: 10.1186/s12889-020-09712-3
pii: 10.1186/s12889-020-09712-3
pmc: PMC7594426
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1621Subventions
Organisme : NIMH NIH HHS
ID : R01MH098744
Pays : United States
Organisme : NIMH NIH HHS
ID : K24 MH114732
Pays : United States
Organisme : Office of International Science and Engineering (US)
ID : AID-OAA-A-12-00023
Organisme : National Institute of Mental Health (US)
ID : R01MH095507
Organisme : Bill and Melinda Gates Foundation
ID : OPP1056051
Références
J Acquir Immune Defic Syndr. 2019 Nov 1;82(3):265-274
pubmed: 31609925
BMC Med Ethics. 2018 Jan 11;19(1):3
pubmed: 29325536
PLoS Med. 2013;10(9):e1001511
pubmed: 24058300
Dev Rev. 2008 Mar;28(1):78-106
pubmed: 18509515
Sex Transm Infect. 2020 Mar;96(2):121-123
pubmed: 31350378
N Engl J Med. 2012 Aug 2;367(5):399-410
pubmed: 22784037
AIDS Patient Care STDS. 2012 Feb;26(2):87-94
pubmed: 22149764
AIDS. 2015 Jul 17;29(11):1277-85
pubmed: 26103095
Lancet HIV. 2017 Nov;4(11):e475
pubmed: 29096785
N Engl J Med. 2015 Feb 5;372(6):509-18
pubmed: 25651245
MMWR Morb Mortal Wkly Rep. 2016 Dec 02;65(47):1332-1335
pubmed: 27906910
Gates Open Res. 2017 Nov 6;1:3
pubmed: 29355231
N Engl J Med. 2012 Aug 2;367(5):411-22
pubmed: 22784040
N Engl J Med. 2010 Dec 30;363(27):2587-99
pubmed: 21091279
Int J STD AIDS. 2016 Apr;27(5):377-86
pubmed: 25931238
Ann Allergy Asthma Immunol. 2018 Jul;121(1):65-68.e1
pubmed: 29730013
J Int Assoc Provid AIDS Care. 2019 Jan-Dec;18:2325958219831011
pubmed: 30776954
Nat Neurosci. 2004 Oct;7(10):1040-7
pubmed: 15452575
J Int AIDS Soc. 2019 Feb;22(2):e25232
pubmed: 30746898
J Acquir Immune Defic Syndr. 2018 Jan 1;77(1):41-45
pubmed: 29016523
Int J Oral Maxillofac Surg. 2001 Jun;30(3):216-9
pubmed: 11420904
BMC Infect Dis. 2016 Oct 17;16(1):571
pubmed: 27751179
J Am Acad Child Adolesc Psychiatry. 2010 Dec;49(12):1189-201; quiz 1285
pubmed: 21093769
AIDS. 2017 Jul 31;31(12):1709-1714
pubmed: 28700394
Lancet Infect Dis. 2014 Sep;14(9):820-9
pubmed: 25065857
J Acquir Immune Defic Syndr. 2018 Nov 1;79(3):330-338
pubmed: 30063651
J Int AIDS Soc. 2017 Jul 25;20(1):21842
pubmed: 28741331
JAMA Intern Med. 2016 Jan;176(1):75-84
pubmed: 26571482
J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):463-8
pubmed: 22267018
AIDS Behav. 2018 Jun;22(6):1758-1765
pubmed: 28894986
J Acquir Immune Defic Syndr. 2013 Mar 1;62(3):339-47
pubmed: 23187945
J Int AIDS Soc. 2020 Mar;23(3):e25466
pubmed: 32144888
Curr Opin HIV AIDS. 2017 Mar;12(2):175-181
pubmed: 28079591
J Acquir Immune Defic Syndr. 2017 Jan 1;74 Suppl 1:S15-S22
pubmed: 27930607